MedTrace Logo

Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10%

NCT03596099 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2019-07-30

No results posted yet for this study

Summary

This study is to assess the blood pressure lowering effect of rice vinegar when consumed over a 12-week period by healthy adults ages 30-65 years old with prehypertension. Study subjects will be recruited online via ClaimIt software platform and randomized to receive either the active rice vinegar-based drink or placebo and will visit the Endothelix research study site in Houston, Texas, 6 times during the study (Week -2, 0, 4, 8, 12 and 16). Here, subjects will undergo blood pressure monitoring, endothelial function, and laboratory assessments.

Conditions

  • Prehypertension

Interventions

DIETARY_SUPPLEMENT

Mizkan rice vinegar with acetic acid

200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.

DIETARY_SUPPLEMENT

Mizkan rice vinegar without acetic acid

200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid

Sponsors & Collaborators

  • ObvioHealth

    collaborator INDUSTRY

  • Endothelix

    collaborator UNKNOWN

  • Mizkan Holdings Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lydia Bazzano, MD, PhD · Tulane University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-11
Primary Completion
2019-07-31
Completion
2019-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03596099 on ClinicalTrials.gov